Encompass Health Corporation (NYSE:EHC – Get Free Report) CEO Mark Tarr sold 150,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $111.64, for a total transaction of $16,746,000.00. Following the completion of the transaction, the chief executive officer directly owned 377,070 shares of the company’s stock, valued at approximately $42,096,094.80. The trade was a 28.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Encompass Health Stock Down 1.1%
Shares of Encompass Health stock traded down $1.27 during trading hours on Thursday, reaching $112.16. 2,129,835 shares of the company were exchanged, compared to its average volume of 1,486,056. The firm has a market cap of $11.29 billion, a PE ratio of 20.25, a PEG ratio of 2.07 and a beta of 0.73. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.14 and a current ratio of 1.08. Encompass Health Corporation has a 1 year low of $92.53 and a 1 year high of $127.99. The stock’s fifty day moving average is $104.00 and its 200 day moving average is $114.49.
Encompass Health (NYSE:EHC – Get Free Report) last released its earnings results on Thursday, February 5th. The company reported $1.46 earnings per share for the quarter, topping analysts’ consensus estimates of $1.29 by $0.17. Encompass Health had a net margin of 9.54% and a return on equity of 18.20%. The firm had revenue of $3.09 billion for the quarter, compared to analyst estimates of $1.54 billion. During the same period in the prior year, the firm earned $1.17 earnings per share. The business’s quarterly revenue was up 9.9% compared to the same quarter last year. Encompass Health has set its FY 2026 guidance at 5.810-6.100 EPS. As a group, equities research analysts forecast that Encompass Health Corporation will post 4.8 earnings per share for the current year.
Hedge Funds Weigh In On Encompass Health
Wall Street Analyst Weigh In
EHC has been the topic of several research analyst reports. Zacks Research lowered Encompass Health from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 19th. Raymond James Financial raised shares of Encompass Health to a “strong-buy” rating in a research report on Friday, October 31st. Wall Street Zen raised Encompass Health from a “hold” rating to a “buy” rating in a research note on Sunday, January 18th. Finally, Barclays lifted their price target on shares of Encompass Health from $150.00 to $153.00 and gave the company an “overweight” rating in a report on Friday, February 6th. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, Encompass Health currently has an average rating of “Buy” and a consensus target price of $143.29.
Check Out Our Latest Research Report on Encompass Health
Encompass Health Company Profile
Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.
Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.
Read More
- Five stocks we like better than Encompass Health
- USAU: The U.S. Gold-Copper Story Investors Can’t Ignore.
- The DoD just got a new drone supplier
- Most Investors Aren’t Looking at This Side of Clean Energy
- My Epstein Story
- When to buy gold (mathematically)
Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.
